$EAPH Provides Regulatory Filing Update for Its EvaPro

Ackerman Pharma, a consultancy company Easton Pharmaceuticals and its partner BMV Medica have retained to acquire regulatory approval in Mexico and other Latin America markets for various products they both co-own distribution rights to, have been informed that its regulatory submission for EvaPro: VagiSan (vaginal discharge diagnostic) in Mexico is expected to be filed with the Mexican Ministry of Health within the next 14 days. Once submitted, it is expected that government approval will be granted within 40 days, given that the products are currently approved and being marketed and sold through various multi-national pharmaceutical companies such as German based Bayer Pharmaceuticals in Europe and presently being sold within the United States and Canada. BMV is expecting to deliver to the manufacturer an initial order within the next few weeks for an estimated 3 month delivery time which demonstrates its confidence in a quick approval and eventual sales.

Easton Pharmaceuticals / BMV are currently working towards closing on discussions for distribution through regional or multi-national pharmaceutical companies in Latin American markets to distribute its full line of exclusive, patented approved products outlined below. Easton believes the best course of action for these products is to build relationships with specialized companies to initiate sales of its approved products in Mexico and the rest of Latin America. Below is a list and description of currently approved products.

VS-Sense (VagiSan) Diagnostic Test Approval
In addition to the approved products that can be immediately marketed and sold is the approval of the VS-Sense product for most Latin American countries except for Argentina and Chile where Easton / BMV can immediately start to market and sell the product based on US, Canadian and EU approvals. Easton is currently establishing relationships with specialized companies to initiate sales of its VS-Sense (VagiSan) product in Mexico and the rest of Latin America.

AL-Sense Amniotic Fluid Diagnostic Test
Easton Pharmaceuticals and its partner BMV own the rights to the approved amniotic fluid leak test to be called AmnioSense, and is in the process of final packaging for the Latin American market under the EvaPro brand. Sales could begin immediately once commercial alliances have been established in the region. These exclusive licensing rights were jointly purchased by Easton and BMV Medica from Israel-based Common Sense Inc. on a 50/50 profit sharing agreement which encompasses the countries in Central and South America except Brazil. The AmnioSense/AL-Sense Amniotic Fluid Diagnostic Leak Test is a patented women’s diagnostic product that is currently being sold in the United Kingdom, and has European Approval. It serves a huge market, where the birth rate in Latin America is three times the birth rate in North America and most of Europe. The target market for BMV/Easton has a population exceeding 400 million people, half of which are woman. Sales in Latin America for pharmaceutical and diagnostic products are expected to grow at an approximate 15% per annum compared to North America and Europe’s 2-3% growth rate.

GynoFit Lactic Acid Gel Treatment For Bacterial Vaginosis (BV) in Mexico
Already approved in Mexico by the Swiss manufacturer who used a regulatory consultant to approve the product, Easton / BMV have completed the Distribution Agreement including pricing from the manufacturer, and will be placing the first order in anticipation of an April launch. This product is expected to become a big selling product since it can treat the BV successfully without the use of harsh drugs.

The 2 approved products can be sold almost immediately in these countries pending import and packaging. BMV/Easton have commenced discussions for distribution of the products with accredited distribution partners and is in discussions for another approved diagnostic product for Mexico and Latin America

Other Products – Cancer Drugs Paclitaxel, Docetaxel
Easton previously announced it has acquired the rights along with BMV Medica to distribute a full line of generic cancer drugs including Paclitaxel and Docetaxel from Canadian drug manufacturer Biolyse Pharma. After obtaining all documents from Biolyse, presently the largest manufacturer of paclitaxel in Canada, and currently awaiting Canadian regulatory approval for docetaxel, Easton will very shortly be providing an accurate time estimate regarding the filing process and approval of these drugs. Upon approval, Easton and BMV believe they can reasonably obtain up to 20% of the generic cancer drug market in Mexico for each respective drug, representing millions of dollars in potential revenues.

Easton OTC Therapeutic Products (VIORRA, Kenestrin Gel, Skin Renou H.A.)
In conjunction with the patented diagnostic products, Easton is moving towards getting approval to allow the importation of its OTC therapeutic products VIORRA, Kenestrin Gel and Skin Renou H.A. which BMV have currently secured orders in Mexico for but are awaiting importation approval.

Dr. Jose Tiran Saucedo
Easton Pharmaceuticals previously announced the appointment of Dr. Jose Tiran Saucedo as the Founding Member of Easton Pharma’s Medical/ Scientific Advisory Board. In this capacity Dr. Saucedo will advise Easton Pharmaceuticals and partners in planning the Latin American launches of its suite of patented, exclusive women’s health products over the coming months.

Dr. Jose Tiran is a Thought Leader (KOL- Key Opinion Leader) in Gynecological Infectious Diseases, and is a Fellow of the American College of Obstetricians and Gynecologists. He has been a strong advocate over the years in women´s health worldwide. Also, Dr. Tiran has published numerous peer-reviewed papers on the subject, and is also board certified in Mexico, a member of multiple health societies, and holds numerous other prestigious positions in the field of Women’s Health. Dr Tiran is also well versed in other aspects of women’s health such as sexually transmitted diseases, female sexual health, contraception, vaccines and gynecology and women´s health and wellbeing.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women’s diagnostic products and two generic cancer products. Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
https://www.eastonpharmaceuticalsinc.com
https://ecigmarkets.com
https://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.